National cohort for pediatric autoimmune cytopenia
"French National Cohort of Patients With Pediatric-onset of Autoimmune Cytopenia (OBS'CEREVANCE Cohort)"
This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3500 (estimated) |
| Ages | N/A to 17 Years |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 9 sites (Amiens and 8 other locations) |
| Trial ID | NCT05937828 on ClinicalTrials.gov |
What this trial studies
OBS'CEREVANCE is a national prospective cohort initiated in 2004 that focuses on pediatric patients diagnosed with autoimmune cytopenias, including Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), and Evans Syndrome. The cohort, supported by 30 pediatric hematologic centers across France, aims to collect real-world data to understand the long-term health outcomes of these patients, identify genetic factors, and evaluate the benefit-risk balance of various treatments. This comprehensive database serves as a resource for care, education, and research in the field of pediatric autoimmune cytopenias.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with ITP, AIHA, or Evans Syndrome before the age of 18.
Not a fit: Patients whose legal representatives oppose data collection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of pediatric autoimmune cytopenias, potentially enhancing treatment outcomes for affected patients.
How similar studies have performed: Other studies focusing on pediatric autoimmune conditions have shown promise, but this cohort represents a unique and extensive approach to understanding these rare diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ITP, AIHA, Evans Syndrome * Onset before the age of 18 Exclusion Criteria: * Opposition of legal representative or to data collection
Where this trial is running
Amiens and 8 other locations
- CHU Amiens Picardie Service d' Onco-Immuno-Hématologie Pédiatrique — Amiens, France (Recruiting)
- CHU d'Angers Unité d'Hémato-Oncologie Pédiatrique — Angers, France (Recruiting)
- BESANCON CHU de Besançon Hôpital Jean MINJOZ Unité d'Hémato-Oncologie Pédiatrique, Pédiatrie 1 — Besançon, France (Recruiting)
- CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique — Bordeaux, France (Recruiting)
- CHU BREST Hôpital Morvan Unité d'Onco-Hématologie — Brest, France (Recruiting)
- CHU de Caen Unité d'Onco-Hématologie — Caen, France (Recruiting)
- CHU de Clermont Ferrand — Clermont-Ferrand, France (Recruiting)
- APHP Hôpital Bicêtre Service de Pédiatrie générale — Paris, France (Recruiting)
- CH de Cornouaille Service de Pédiatrie — Quimper, France (Recruiting)
Study contacts
- Principal investigator: Nathalie ALADJIDI, MD — University Hospital, Bordeaux
- Study coordinator: Nathalie ALADJIDI, MD
- Email: nathalie.aladjidi@chu-bordeaux.fr
- Phone: +33 557820261
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.